ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 242 filers reported holding ACCELERON PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $178,000 | +27.1% | 1,036 | -7.1% | 0.00% | – |
| Q2 2021 | $140,000 | -7.9% | 1,115 | -0.4% | 0.00% | -100.0% |
| Q1 2021 | $152,000 | -5.0% | 1,120 | -10.6% | 0.00% | 0.0% |
| Q4 2020 | $160,000 | +8.8% | 1,253 | -3.9% | 0.00% | 0.0% |
| Q3 2020 | $147,000 | +26.7% | 1,304 | +7.1% | 0.00% | 0.0% |
| Q2 2020 | $116,000 | -95.2% | 1,217 | -95.4% | 0.00% | -92.3% |
| Q1 2020 | $2,396,000 | +60.3% | 26,660 | -5.5% | 0.01% | +116.7% |
| Q4 2019 | $1,495,000 | +33.0% | 28,201 | -0.8% | 0.01% | +20.0% |
| Q3 2019 | $1,124,000 | -4.4% | 28,439 | -0.7% | 0.01% | 0.0% |
| Q2 2019 | $1,176,000 | -9.1% | 28,637 | +3.1% | 0.01% | 0.0% |
| Q1 2019 | $1,294,000 | +16.6% | 27,783 | +9.1% | 0.01% | 0.0% |
| Q4 2018 | $1,110,000 | -24.4% | 25,477 | -0.8% | 0.01% | 0.0% |
| Q3 2018 | $1,469,000 | +20.1% | 25,672 | +1.8% | 0.01% | +25.0% |
| Q2 2018 | $1,223,000 | +30.4% | 25,210 | +5.1% | 0.00% | +33.3% |
| Q1 2018 | $938,000 | -12.6% | 23,997 | -5.1% | 0.00% | -25.0% |
| Q4 2017 | $1,073,000 | +33.8% | 25,288 | +17.7% | 0.00% | +33.3% |
| Q3 2017 | $802,000 | +32.8% | 21,487 | +8.1% | 0.00% | +50.0% |
| Q2 2017 | $604,000 | +35.1% | 19,880 | +17.8% | 0.00% | 0.0% |
| Q1 2017 | $447,000 | +11.2% | 16,878 | +7.1% | 0.00% | 0.0% |
| Q4 2016 | $402,000 | -99.9% | 15,759 | -0.3% | 0.00% | 0.0% |
| Q3 2016 | $571,838,000 | +6.7% | 15,801 | +0.2% | 0.00% | 0.0% |
| Q2 2016 | $536,102,000 | +59.6% | 15,777 | +24.1% | 0.00% | +100.0% |
| Q1 2016 | $336,000,000 | -45.8% | 12,715 | 0.0% | 0.00% | -66.7% |
| Q4 2015 | $620,000,000 | +195483.6% | 12,715 | -0.2% | 0.00% | +200.0% |
| Q3 2015 | $317,000 | -99.9% | 12,737 | +0.1% | 0.00% | -50.0% |
| Q2 2015 | $402,524,000 | +2.2% | 12,722 | +23.0% | 0.00% | 0.0% |
| Q1 2015 | $393,693,000 | -2.3% | 10,344 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $403,002,000 | +23.9% | 10,344 | -3.8% | 0.00% | +100.0% |
| Q3 2014 | $325,171,000 | -11.0% | 10,753 | -0.1% | 0.00% | -50.0% |
| Q2 2014 | $365,517,000 | +142.2% | 10,760 | +145.9% | 0.00% | +100.0% |
| Q1 2014 | $150,938,000 | -10.5% | 4,375 | +2.7% | 0.00% | 0.0% |
| Q4 2013 | $168,656,000 | – | 4,259 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |